Evidence map›Paper›PMID 42595774›Full record

ReviewJournal of human hypertension2026

Triple drug antihypertensive single-pill combinations included as WHO essential medicines: an overview of efficacy, safety, and cost.

Gautam Satheesh, Abdul Salam, Rupasvi Dhurjati, Paul K Whelton, Pablo Perel, Adrianna Murphy, Dike Ojji, H Asita de Silva, Elijah Ogola, Ntobeko A B Ntusi and 9 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gautam SatheeshThe George Institute for Global Health, Hyderabad, India.ORCID http://orcid.org/0000-0003-2211-145X
Abdul SalamThe George Institute for Global Health, Hyderabad, India.ORCID http://orcid.org/0000-0002-5870-7936
Rupasvi DhurjatiThe George Institute for Global Health, Hyderabad, India.
Paul K WheltonDepartment of Epidemiology, Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.ORCID http://orcid.org/0000-0002-2225-383X
Pablo PerelLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Adrianna MurphyLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Dike OjjiDepartment of Internal Medicine, University of Abuja, Abuja, Nigeria.ORCID http://orcid.org/0000-0002-2084-1988
H Asita de SilvaClinical Trials Unit, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
Elijah OgolaUniversity of Nairobi, Nairobi, Kenya.
Ntobeko A B NtusiSouth African Medical Research Council, South Africa and Department of Medicine, University of Cape Town, Cape Town, South Africa.
Jun CaiBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Thomas A GazianoHarvard Medical School, Brigham & Women's Hospital, Harvard T.H. Chan School of Public Health, Boston, USA.
Dorairaj PrabhakaranCentre for Chronic Disease Control, New Delhi, India.ORCID http://orcid.org/0000-0002-3172-834X
Sohel Reza ChoudhuryNational Heart Foundation Hospital and Research Institute, Dhaka, Bangladesh.ORCID http://orcid.org/0000-0002-7498-4634
Ana G Munera EcheverriInterAmerican Society of Cardiology, Mexico, Colombia.
Mark D HuffmanThe George Institute for Global Health, Sydney, Australia.ORCID http://orcid.org/0000-0001-7412-2519
Aletta E SchutteThe George Institute for Global Health, Sydney, Australia.ORCID http://orcid.org/0000-0001-9217-4937
Andrew E MoranResolve to Save Lives, New York, USA.ORCID http://orcid.org/0000-0003-3554-0085
Anthony RodgersThe George Institute for Global Health, Sydney, Australia. arodgers@georgeinstitute.org.ORCID http://orcid.org/0000-0003-1282-1896

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, only about one in five of the 1.4 billion people with hypertension achieve blood pressure (BP) control to <140/90 mmHg, despite strong evidence and clear guideline recommendations for optimal management. Many patients require three or more antihypertensive medicines, yet real-world barriers, including limited access, poor adherence and health system complexities, prevent them from achieving optimal BP control. Single pill combinations (SPCs) improve adherence, simplify treatment, and enhance efficacy with favourable safety through complementary pharmacological mechanisms at lower, better-tolerated doses. The World Health Organization in 2025 added triple drug antihypertensive SPCs to the 24

Identifiers

PMID42595774

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.